首站-论文投稿智能助手
典型文献
Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis
文献摘要:
Idiopathic pulmonary fibrosis(IPF)is a chronic progressive fibrotic interstitial pneumonia with unknown causes.The incidence rate increases year by year and the prognosis is poor without cure.Recently,phosphatidylinositol 3-kinase(PI3K)/protein kinase B(PKB/AKT)signaling pathway can be considered as a master regulator for IPF.The contribution of the PI3K/AKT in fibrotic processes is increasingly prominent,with PI3K/AKT inhibitors currently under clinical evaluation in IPF.Therefore,PI3K/AKT represents a critical signaling node during fibrogenesis with potential implications for the development of novel anti-fibrotic strategies.This review epitomizes the progress that is being made in understanding the complex interpretation of the cause of IPF,and demonstrates that PI3K/AKT can directly participate to the greatest extent in the formation of IPF or cooperate with other pathways to pro-mote the development of fibrosis.We further summarize promising PI3K/AKT inhibitors with IPF treat-ment benefits,including inhibitors in clinical trials and pre-clinical studies and natural products,and discuss how these inhibitors mitigate fibrotic progression to explore possible potential agents,which will help to develop effective treatment strategies for IPF in the near future.
文献关键词:
作者姓名:
Jincheng Wang;Kaili Hu;Xuanyan Cai;Bo Yang;Qiaojun He;Jiajia Wang;Qinjie Weng
作者机构:
Center for Drug Safety Evaluation and Research,College of Pharmaceutical Sciences,Zhejiang University,Hangzhou 310058,China;Hangzhou Institute of Innovative Medicine,College of Pharmaceutical Sciences,Zhejiang University,Hangzhou 310058,China
引用格式:
[1]Jincheng Wang;Kaili Hu;Xuanyan Cai;Bo Yang;Qiaojun He;Jiajia Wang;Qinjie Weng-.Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis)[J].药学学报(英文版),2022(01):18-32
A类:
epitomizes
B类:
Targeting,PI3K,AKT,signaling,treatment,idiopathic,pulmonary,fibrosis,Idiopathic,IPF,chronic,progressive,fibrotic,interstitial,pneumonia,unknown,causes,incidence,increases,year,by,prognosis,poor,without,cure,Recently,phosphatidylinositol,kinase,protein,PKB,can,considered,master,regulator,contribution,processes,increasingly,prominent,inhibitors,currently,clinical,evaluation,Therefore,represents,critical,node,during,fibrogenesis,potential,implications,development,novel,anti,strategies,This,review,that,being,made,understanding,complex,interpretation,demonstrates,directly,participate,greatest,extent,formation,cooperate,other,pathways,mote,We,further,summarize,promising,benefits,including,trials,studies,natural,products,discuss,how,these,mitigate,progression,explore,possible,agents,which,will,help,effective,near,future
AB值:
0.564349
相似文献
Pirfenidone ameliorates silica-induced lung inflammation and fibrosis in mice by inhibiting the secretion of interleukin-17A
Zhu-jie Cao;Ying Liu;Zhe Zhang;Pei-ran Yang;Zhao-guo Li;Mei-yue Song;Xian-mei Qi;Zhi-fa Han;Jun-ling Pang;Bai-cun Li;Xin-ri Zhang;Hua-ping Dai;Jing Wang;Chen Wang-State Key Laboratory of Medical Molecular Biology,Institute of Basic Medical Sciences,Chinese Academy of Medical Sciences,Beijing 100005,China;Department of Pathophysiology,Peking Union Medical College,Beijing 100005,China;Department of Pulmonary and Critical Care Medicine,the First Hospital of Shanxi Medical University,Taiyuan 030001,China;Department of Respiratory,the Second Affiliated Hospital of Harbin Medical University,Harbin 150086,China;Beijing University of Chinese Medicine,Beijing 100029,China;Department of Pulmonary and Critical Care Medicine,Center of Respiratory Medicine,China-Japan Friendship Hospital,Beijing 100029,China;National Center for Respiratory Medicine;Institute of Respiratory Medicine,Chinese Academy of Medical Sciences;National Clinical Research Center for Respiratory Diseases,Beijing 100029,China
Discovery of a novel DDRs kinase inhibitor XBLJ-13 for the treatment of idiopathic pulmonary fibrosis
Ying Dong;Bi-xi Tang;Qi Wang;Li-wei Zhou;Cong Li;Xuan Zhang;Dan-dan Sun;Xin Sun;Xue-mei Zhang;Bing Xiong;Jia Li;Hong Shi;Dan-qi Chen;Yi Zang-State Key Laboratory of Drug Research,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;University of Chinese Academy of Sciences,Beijing 100049,China;Department of Pharmacology,School of Pharmacy,Fudan University,Shanghai 201203,China;Department of Medicinal Chemistry,Shanghai Institute of Materia Medica,Chinese Academy of Sciences,Shanghai 201203,China;Center for Supramolecular Chemistry and Catalysis and Department of Chemistry,College of Sciences,Shanghai University,Shanghai 200444,China;Schoolof Chinese Materia Medica,Nanjing University of Chinese Medicine,Nanjing 210023,China;Schoolof Pharmacy,Henan University,Kaifeng 475004,China;Open Studio for Druggability Research of Marine Natural Products,Pilot National Laboratory for Marine Science and Technology(Qingdao),Qingdao 266237,China;School of Pharmaceutical Science and Technology,Hangzhou Institute for Advanced Study,UCAS,Hangzhou 310024,China;Department of Anesthesiology of Shanghai Pulmonary Hospital,School of medicine,Tongji University,Shanghai 200433,China
机标中图分类号,由域田数据科技根据网络公开资料自动分析生成,仅供学习研究参考。